Porcine FSH API for use in donor cow superovulation is most frequently presented as a sterile lyophilised cake intended for intramuscular injection after reconstitution; the nominal active loading of 400 mg NIH-FSH-P1 per single-dose vial, when reconstituted to 20 mL, yields a nominal strength of 20 mg/mL. Finished-product release under the European Pharmacopoeia monograph for follitropin for veterinary use (Ph. Eur. 1698) includes sterility testing by Ph. Eur. 2.6.1, bacterial endotoxin control by Ph. Eur. 2.6.14 with a typical limit of 0.5 EU/mg for injectable peptide preparations, and an in vivo ovarian weight gain bioassay to confirm specific activity. Compounding is carried out in a Grade C cleanroom (ISO 14644-1 Class 7) with critical operations in Grade A laminar airflow (ISO 14644-1 Class 5); the API is dissolved in water for injection at 20–25°C, buffered to pH 7.0 ± 0.2 with phosphate or citrate, and filtered through a 0.22 µm PVDF membrane at a flux of 15–20 L/h/m² before aseptic filling into Type I borosilicate glass vials conforming to ISO 8362-1, with a nitrogen overlay maintaining headspace oxygen below 2% where validated. The freeze-drying cycle is site-specific, but production-scale units commonly use shelf freezing at -45°C for no less than 180 min, primary drying at -20°C and 80–120 µbar chamber pressure for 24–36 h, and secondary drying at 25°C for 6–10 h; published FSH-specific collapse temperature data is limited, so cycle development relies on freeze-drying microscopy and modulated differential scanning calorimetry rather than fixed generic cycles. Field batch records from embryo transfer centres report that the principal failure mode is incomplete cake dissolution when the diluent temperature is below 15°C; under these conditions reconstitution can exceed 120 s and visible aggregates may appear, even though the cake was released as sterile and within specification. The terminal finished product is a single-dose lyophilised powder for injection supplied in 10 mL or 20 mL vials and reconstituted immediately before use; no terminal sterilisation is applied because dry heat or steam exposure would denature the glycoprotein and reduce bioactivity below the label claim.

Tablet, capsule, granule and premix presentations are not included in this application page because FSH is a glycoprotein that is denatured at gastric pH and degraded by pancreatic proteases; no validated oral delivery system for veterinary FSH is described in the current European Pharmacopoeia monograph or VICH guidance, and feed or drinking water administration would not provide reproducible systemic exposure.

What Limits Reconstitution Time in Ovine FSH Lyophilisates to Under 120 Seconds?

Ovine and caprine superovulation protocols require a lower total active loading than bovine MOET; published flock protocols specify 200–300 mg NIH-FSH-P1 per donor ewe and 70–150 mg per donor goat, administered as six descending intramuscular injections over 3 days to avoid follicle-stimulating hormone receptor downregulation. The lyophilisate for small ruminants is typically formulated with a bulking agent at 2–5% w/v, using mannitol for crystalline cake structure or glycine for amorphous collapse resistance, and the active-to-bulking-agent ratio is adjusted so that the reconstituted volume remains 10–20 mL per vial. Compliance for this presentation is identical at monograph level to the bovine product, but the lower cake height changes the lyophilisation risk profile; primary drying must remain below the collapse temperature of the specific bulking-agent phase, and freeze-drying microscopy shows that mannitol-rich cakes can tolerate a shelf temperature 3–5°C higher than glycine-rich cakes at the same chamber pressure. Downstream production therefore uses separate cycle recipes for small-ruminant and bovine presentations, even when the same API lot is used. Reconstitution time is a critical in-clinic quality attribute; production-scale experience shows that pre-wetting the cake with 2 mL of diluent before making up to final volume reduces reconstitution time to under 120 s, whereas direct addition of the full diluent volume can trap dry powder in the vial shoulder and require vigorous agitation. The terminal finished product is a single-dose lyophilised powder for injection in 200 mg or 300 mg active loading vials, accompanied by sterile diluent ampoules; once reconstituted, the solution should be used within 6 hours when held at 2–8°C because published stability data for diluted FSH beyond this interval is limited.

Porcine gilt synchronisation utilises the same FSH API in a preservative-free aqueous solution rather than a lyophilisate because ready-to-use liquid vials reduce handling steps in commercial pig units; however, the absence of lyoprotectants reduces storage stability and imposes a cold-chain requirement of 2–8°C. Published field protocols for prepubertal gilt induction and fixed-time artificial insemination describe total doses of 100–200 mg NIH-FSH-P1 per gilt, divided into 4–6 intramuscular injections over 2–3 days, often followed by an hCG trigger to synchronise ovulation. Industry compliance for the liquid presentation includes Ph. Eur. 1698 for the active substance, Ph. Eur. 5.1.1 for aseptic preparation, and Ph. Eur. 2.6.14 for endotoxins; because FSH is an endogenous peptide hormone, regulatory dossiers commonly state that no maximum residue limit is required under Commission Regulation (EU) No 37/2010, but national approval for food-producing species still requires demonstration of appropriate withdrawal management under Regulation (EU) 2019/6. Downstream production proceeds by dissolving the API in water for injection at 20–25°C, adjusting osmolality to 280–320 mOsm/kg with sodium chloride or mannitol, and filtering through a 0.22 µm membrane before aseptic filling into Type I glass vials; no terminal sterilisation is applied because FSH is heat-labile, and bacterial retention is assured only by the sterilising filter and aseptic technique. The production bottleneck on liquid filling lines is foaming caused by the protein at high fill speeds; rotary piston pumps with bottom-up filling nozzles reduce foam and maintain dose uniformity within ±3% of label claim. Published data on liquid FSH aggregation kinetics in porcine formulations is limited, so real-time stability at 2–8°C is used to assign expiry rather than accelerated predictive modelling. The terminal finished product is a sterile injectable solution, typically 10 mL single-dose vials containing 20 mg/mL FSH.

Reconstitution Shear and pH Drift in Compounded Camelid Embryo Transfer Doses

Alpaca and llama embryo transfer programmes often begin with a licensed porcine FSH lyophilisate and dilute it to a lower concentration for species-specific protocols; the dominant processing variable in this downstream use is not lyophilisation but reconstitution shear and pH control after dilution. Reported protocols describe total doses of 100–200 mg NIH-FSH-P1 per donor camelid, with some clinicians escalating to 250 mg in animals that fail to produce multiple corpora lutea; published data for this specific configuration is limited, and most dose justifications are based on porcine or ovine extrapolation. Compliance for extemporaneous compounding falls under national veterinary compounding rules rather than finished-product marketing authorisation, but the quality benchmarks for aseptic handling remain Ph. Eur. 5.1.1, Ph. Eur. 2.6.1, and Ph. Eur. 2.6.14. Compounding is performed by adding 0.9% sodium chloride injection gently down the vial wall, swirling rather than shaking, and avoiding vortexing because FSH is a glycoprotein susceptible to shear-induced aggregation at air-liquid interfaces. The diluted solution is held at 2–8°C and used within 4 hours; extended storage beyond this window is not supported by published stability data. The terminal product is an extemporaneous injectable solution in single-use syringes or sterile vials, usually at 10 mg/mL to 20 mg/mL depending on the volume to be administered.

In equine veterinary reproduction, where no centrally authorised FSH product is available in most jurisdictions, the API is compounded into an intramuscular solution for donor mares; the finished preparation is therefore a pharmacy-compounded injectable rather than a licensed commercial presentation. Extralabel use in the United States falls under 21 CFR Part 530, and the preparation is expected to follow the same aseptic compounding principles as Ph. Eur. 5.1.1; practitioners may also reference USP <797> as a quality guide even though it is written for human preparations. Published equine case series report a total dose of 12.5 mg equine-derived FSH per mare injected intramuscularly at 12-hour intervals for 3–4 days, but published data for this specific configuration is limited, and many equine clinics instead use porcine FSH at equivalent NIH-FSH-P1 doses under extralabel provisions. The compounding process involves reconstituting the lyophilised API with sterile water for injection to 5 mg/mL or 10 mg/mL, filtering through a 0.22 µm syringe filter only if particulate matter is visible, and storing at 2–8°C for not more than 24 hours. Terminal product type is an injectable solution dispensed in individual syringes or single-dose vials.